JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB142172

PX-866, PI3-kinase inhibitor

Be the first to review this product! Submit a review

|

(0 Publication)

MW 525.6 Da, Purity >98%. Potent, irreversible PI3-kinase inhibitor. Inhibits purified phosphoinositide (PtdIns)-3-kinase (IC50 = 0.1 nM) and PtdIns-3-kinase signaling as assessed by phospho-Ser473-Akt levels in HT-29 colon cancer cells (IC50 = 20 nM). Ring-​opened analog of wortmannin (ab120148). Displays antitumor activity.

View Alternative Names

5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha, 5-bisphosphate 3-kinase catalytic subunit alpha isoform, CLOVE, CWS5, FK506 binding protein 12 rapamycin associated protein 1, FK506 binding protein 12 rapamycin associated protein 2, FK506-binding protein 12-rapamycin complex-associated protein 1, FKBP rapamycin associated protein, FKBP12-rapamycin complex-associated protein, FKBP12-rapamycin complex-associated protein 1, FLJ44809, FRAP, FRAP1, FRAP2, KAPCG_HUMAN, KAPG, MCAP, MCM, MCMTC, MGC142161, MGC142163, MTOR_HUMAN, Mammalian target of rapamycin, Mechanistic target of rapamycin, OTTHUMP00000001983, PI 3 Kinase catalytic subunit alpha, PI3 kinase p110 subunit alpha, PI3-kinase subunit alpha, PI3K, PI3K-alpha, PI3KC A, PIK3C A, PK3CA_HUMAN, PKA C-gamma, PKACg, PRKACG, Phosphatidylinositol 3 kinase catalytic alpha polypeptide, Phosphatidylinositol 3 kinase catalytic 110 KD alpha, Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha, Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha isoform, Phosphatidylinositol 4,5 bisphosphate 3 kinase 110 kDa catalytic subunit alpha, Phosphatidylinositol-4, Phosphoinositide 3 kinase catalytic alpha polypeptide, Protein kinase cAMP dependent catalytic gamma, PtdIns 3 kinase p110, PtdIns-3-kinase subunit alpha, PtdIns-3-kinase subunit p110-alpha, RAFT1, RAPT1, Rapamycin and FKBP12 target 1, Rapamycin associated protein FRAP2, Rapamycin target protein, Rapamycin target protein 1, Serine (threonine) protein kinase, Serine/threonine protein kinase PIK3CA, Serine/threonine-protein kinase mTOR, cAMP-dependent protein kinase catalytic subunit gamma, caPI3K, dJ576K7.1 (FK506 binding protein 12 rapamycin associated protein 1), p110 alpha

1 Images
Chemical Structure - PX-866, PI3-kinase inhibitor (AB142172)
  • Chemical Structure

Lab

Chemical Structure - PX-866, PI3-kinase inhibitor (AB142172)

2D chemical structure image of ab142172, PX-866, PI3-kinase inhibitor

Key facts

CAS number

502632-66-8

Purity

>98%

Form

Solid

form

Molecular weight

525.6 Da

Molecular formula

C<sub>2</sub><sub>9</sub>H<sub>3</sub><sub>5</sub>NO<sub>8</sub>

PubChem

9849735

Nature

Synthetic

Solubility

Soluble in DMSO to 50 mM

Biochemical name

Sonolisib

Biological description

Potent, irreversible PI3-kinase inhibitor. Inhibits purified phosphoinositide (PtdIns)-3-kinase (IC50 = 0.1 nM) and PtdIns-3-kinase signaling as assessed by phospho-Ser473-Akt levels in HT-29 colon cancer cells (IC50 = 20 nM). Ring-​opened analog of wortmannin (ab120148). Displays antitumor activity.

Canonical smiles

CC(=O)OC1CC2(C(CCC2=O)C3=C1C4(C(OC(=O)C(=CN(CC=C)CC=C)C4=C(C3=O)O)COC)C)C

Isomeric smiles

CC(=O)O[C@@H]1C[C@]2([C@@H](CCC2=O)C3=C1[C@]4([C@H](OC(=O)/C(=C/N(CC=C)CC=C)/C4=C(C3=O)O)COC)C)C

InChi

InChI=1S/C29H35NO8/c1-7-11-30(12-8-2)14-17-23-26(34)25(33)22-18-9-10-20(32)28(18,4)13-19(37-16(3)31)24(22)29(23,5)21(15-36-6)38-27(17)35/h7-8,14,18-19,21,34H,1-2,9-13,15H2,3-6H3/b17-14+/t18-,19+,21+,28-,29-/m0/s1

InChiKey

QIUASFSNWYMDFS-NILGECQDSA-N

IUPAC Name

[(3aR,6E,9S,9aR,10R,11aS)-6-[[bis(prop-2-enyl)amino]methylidene]-5-hydroxy-9-(methoxymethyl)-9a,11a-dimethyl-1,4,7-trioxo-2,3,3a,9,10,11-hexahydroindeno[4,5-h]isochromen-10-yl] acetate

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Storage information
Store under desiccating conditions

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The mechanistic target of rapamycin known as mTOR plays an important role in cellular growth and metabolism. mTOR belongs to the phosphatidylinositol 3-kinase-related kinase family and weighs approximately 289 kDa. It operates mainly in two complexes mTORC1 and mTORC2 each differing in function and structure. PIK3CA another key component specifically acts as a catalytic subunit and is often associated with Class I PI3K. The gene expression of mTOR and PIK3CA occurs ubiquitously but they show higher activity in tissues experiencing rapid growth like muscle and liver. PRKACG or protein kinase A catalytic subunit gamma functions as an important signaling protein across many cell types.
Biological function summary

MTOR regulates the cell cycle cell growth and protein synthesis by integrating signals from nutrients and energy status. Within the cell mTORC1 and mTORC2 belong to separate biochemical complexes that are regulating a range of functions. PI3 kinase activity of PIK3CA facilitates the activation of mTORC1 by generating phosphatidylinositol-345-trisphosphate (PIP3) important for subsequent protein activation steps. PRKACG engages in signaling pathways promoting cellular responses through cyclic adenosine monophosphate (cAMP). Together these components orchestrate cellular metabolic demands with extracellular growth signals.

Pathways

These proteins participate prominently in the PI3K/AKT/mTOR signaling pathway critical for cellular proliferation and survival. This pathway includes a sequence beginning with PI3 kinase's conversion of phosphatidylinositol to PIP3 leading to AKT activation. The pathway concludes with mTOR activation further regulating ribosomal protein S6 kinase and eukaryotic initiation factor 4E-binding protein. Another related pathway is the cAMP signaling pathway where PRKACG contributes through protein kinase A-mediated activation mechanisms. These pathways are engaged with proteins like AKT as well as ribosomal proteins indicating intricate interdependencies.

Dysregulation of the PI3K/AKT/mTOR signaling pathway often correlates with cancer particularly in mutations of PIK3CA which enhance PI3 kinase activity and promote unchecked cellular proliferation. Similarly mTOR malfunction has links with diabetes specifically through insulin resistance where mTORC1 affects glucose metabolism. PRKACG's abnormal activity also appears in certain cancers highlighting its role in different signaling cascades. Connections between mTOR PIK3CA and AKT highlight the complexity of cancer pathophysiology pointing to potential therapeutic targets within these pathways.

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com